Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Eur J Neurol · 2022 · PMC9290576 · PMID 33724637

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

At OLE Year 4.5, the proportion of patients who required a walking aid confirmed for ≥24 weeks was numerically lower in OCR–OCR continuers versus IFN–OCR switchers, but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.